États-Unis · Plateformes & données · Stocktwits

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

Publié par Stocktwits · États-Unis il y a 8 h

Résumé détaillé

The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.

Lire l'article complet sur Stocktwits Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stocktwits.com)

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

Résumé détaillé

À lire aussi

Rumble (NASDAQ:RUM) Shares Up 11.8% - Here's Why

GAMCO Natural Resources Gold & Income Trust declares $0.06 dividend

Need money for a down payment? More employers are offering to help.

Chime at KBW fintech ecosystem conference: growth and margins rise

Fed's Goolsbee calls inflation report 'borderline disturbing' as central bank weighs more hikes

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

Résumé détaillé

Partager

À lire aussi

Rumble (NASDAQ:RUM) Shares Up 11.8% - Here's Why

GAMCO Natural Resources Gold & Income Trust declares $0.06 dividend

Need money for a down payment? More employers are offering to help.

Chime at KBW fintech ecosystem conference: growth and margins rise

Fed's Goolsbee calls inflation report 'borderline disturbing' as central bank weighs more hikes

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030